Spyre Therapeutics (SYRE) Stock Price, Quote, News & History | Benzinga

Spyre Therapeutics Inc (SYRE) Stock Price, Quote, News & History

SYRENASDAQ

Trade with Public

Trade with Public

$90.36

-3.25-3.48%

At close: Aug 28, 5:00 PM EST

$90.05

-0.31-0.34%

After Hours: 5:39 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$91.75

Close

$90.36

Volume / Avg.

1.27M / 1.28M

Day Range

$89.45 - $93.39

52 Wk Range

14.51 - 110.18

Market Cap

$7.77B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

36

Short Interest

14.6%

Days to Cover

15.95

Recent Spyre Therapeutics Inc News

Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles

Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy missed internal priority benchmarks.

Vandana Singh

Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market trading.

Avi Kapoor

Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares rise 3.6% in pre-market trading.

Avi Kapoor

Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.

Avi Kapoor

Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday

Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-208.94M

Investing Cash Flow (TTM)

-463.74M

Financing Cash Flow (TTM)

753.03M

Free Cash Flow (TTM)

-208.94M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

80.35M

Analyst Trends and Forecast

2

May

3

Jun

1

Jul

7

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$6.97B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

8.65

Earnings Yield % (TTM)

-2.05%

Earnings Yield % (FWD)

-3.53%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$10.83

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$162.01M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$91.75

Close

$90.36

Volume / Avg.

1.27M / 1.28M

Day Range

$89.45 - $93.39

52 Wk Range

14.51 - 110.18

Market Cap

$7.77B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

36

Short Interest

14.6%

Days to Cover

15.95

About

Sector

Health Care

Industry

Biotechnology

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes exten...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Spyre Therapeutics (SYRE) stock?

A

You can purchase shares of Spyre Therapeutics (NASDAQ:SYRE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Spyre Therapeutics (SYRE) competitors?

A

Other companies in Spyre Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Spyre Therapeutics (SYRE) stock?

A

Spyre Therapeutics has a consensus price target of $99.00.

Q

What is the current price for Spyre Therapeutics (SYRE)?

A

The stock price for Spyre Therapeutics (NASDAQ: SYRE) is $90.05 last updated August 28, 2026 at 5:39 PM EDT.

Q

Does Spyre Therapeutics (SYRE) pay a dividend?

A

There are no upcoming dividends for Spyre Therapeutics.

Q

When is Spyre Therapeutics (NASDAQ:SYRE) reporting earnings?

A

Spyre Therapeutics does not have any upcoming earnings scheduled.

Q

Is Spyre Therapeutics (SYRE) going to split?

A

There is no upcoming split for Spyre Therapeutics.

Q

What sector and industry does Spyre Therapeutics (SYRE) operate in?

A

Spyre Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.